Delta-9-tetrahydrocannabinol detection method

• US 7,790,400 B2
• Filed: 07/01/2005
• Issued: 09/07/2010
• Est. Priority Date: 07/02/2004
• Status: Expired due to Fees

• Current Assignee: Concateno UK Limited (Abbott Laboratories)
• Original Assignee: Concateno UK Limited (Abbott Laboratories)
• Inventors: Jehanli, Ahmed Mohammed Taki, Hand, Christopher William
• Primary Examiner(s): CHEU, CHANGHWA J
• Application Number:
  US11/630,583
• Publication Number:
  US 20090017555A1
• Time in Patent Office: 1,894 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: G01N 33/50 Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5038 involving detection of metabolites per se
• CPC Class Codes: G01N 33/526 the element being adapted for a specific analyte
• CPC Class Codes: G01N 33/94 involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
• CPC Class Codes: G01N 33/948 Sedatives, e.g. cannabinoids, barbiturates opiates G01N33/9486

Abstract

The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (cannabis; THC) employing a carrier conjugate of an intermediate in the biosynthesis of cannabis, more particularly 5-pentylresorcinol conjugated to a macromolecular carrier via its hydroxyl groups. By employing such a conjugate with anti-THC antibody in a lateral flow immunochromatography test device convenient on-site testing for low levels of cannabis in liquid samples may be achieved. Such testing is particularly favoured for roadside testing for cannabis in oral fluid samples.

Claims

1. A method for detecting in a liquid sample delta-9-tetrahydrocannabinol (THC) or one or more of THC and its metabolites 11-nor-9-carboxy-delta-9-THC (THC-COOH) and 11-hydroxy-delta-9-THC (THC-OH), which comprises:

(a) contacting said sample with (i) a 5-pentylresorcinol/macromolecular carrier conjugate wherein 5-pentylresorcinol is conjugated via a hydroxyl group or a derivative thereof on its benzene ring to the carrier and (ii) an antibody capable of binding both THC and said conjugate; and

(b) determining whether binding of said antibody to said conjugate is reduced in the presence of said sample,

wherein said antibody may exhibit cross-reactivity with said metabolites and reduction of the binding of said antibody to said conjugate is indicative of the presence of THC or the presence of one or more of THC, THC-COOH and THC-OH.

2. The method as claimed in claim 1 wherein said antibody is capable of binding all of delta-9 tetrahydrocannabinol (THC), 11-nor-9-carboxy-delta-9-THC (THC-COOH) and 11-hydroxy-delta-9-THC (THC-OH), whereby one or more of THC, THC-COOH and THC-OH may be detected in the liquid sample.

3. The method as claimed in claim 2 wherein said antibody is an antibody raised to THC-COOH coupled to a carrier protein via its carboxylate group.

4. The method as claimed in claim 1 wherein the carrier of said 5-pentylresorcinol/carrier conjugate is a protein.

5. The method as claimed in claim 4 wherein said protein is selected from the group consisting of bovine serum albumin, horseradish peroxidase, ovalbumin, a gamma globulin, and thyroglobulin.

6. The method as claimed claim 1 wherein said antibody is labeled directly or indirectly.

7. The method of claim 1, wherein said 5-pentylresorcinol conjugate is labeled directly or indirectly or the carrier of said conjugate also serves as a detectable label.

8. The method of claim 1, wherein said conjugate is a conjugate obtained by coupling 5-pentylresorcinol via its hydroxyl groups to amino groups of said carrier using dimethyl aminopyridine/disuccinimidyl carbonate or vinyl sulfone.

9. The method of claim 1, wherein 5-pentylresorcinol is coupled to said carrier via a spacer molecule.

10. The method of claim 1, wherein one of said antibody and said 5-pentylresorcinol/carrier conjugate is immobilised on a solid support.

11. The method of claim 10, wherein the solid support is used in a lateral flow chromatography assay.

12. The method of claim 11, wherein said 5-pentylresorcinol conjugate is immobilised in an analyte detection zone on a test strip or sheet and said antibody is labeled.

13. The method of claim 12, wherein said antibody is gold particle labeled.

14. The method of claim 1, wherein said liquid sample is derived from, urine, blood, sweat, ocular fluid, saliva, or hair.

15. The method of claim 12, wherein the sample applied to the test strip or sheet is buffered-diluted oral fluid.

16. A test strip or sheet for use in a lateral flow analytical device for a carrying out a lateral flow immunochromatography assay, said test strip or sheet comprising:

(i) a strip or sheet comprising a dry porous material having immobilised thereon in an analyte detection zone (a) a 5-pentylresorcinol/macromolecular carrier conjugate wherein 5-pentylresorcinol is conjugated via a hydroxyl group or a derivative thereof on its benzene ring to the carrier, or (b) an antibody capable of binding both THC and said conjugate; and

(ii) joined to, or integral to, said strip or sheet providing said analyte detection zone, a label release zone containing either said antibody in labeled form, if said analyte detection zone presents immobilized 5-pentylresorcinol/carrier conjugate, or, if said analyte detection zone presents immobilized antibody, detectable 5-pentylresorcinol conjugate, whereby said labeled antibody or detectable conjugate will be released into a liquid sample drawn into the label release zone.

17. The test strip or sheet according to claim 16 wherein said dry porous material is nitrocellulose.

18. The test strip or sheet according to claim 16 wherein 5-pentylresorcinol conjugate is immobilised in an analyte detection zone.

19. The test strip or sheet of claims 16, which further comprises a control zone which is located distal to said analyte detection zone in the direction of intended liquid flow.

20. The test strip or sheet of claim 16, which further comprises a sample receiving member or pad proximal to said label release zone having regard to the intended direction of liquid flow.

21. The test strip or sheet of claim 16, which further comprises an absorbent waste pad distal to said analyte detection zone in the direction of intended liquid flow.

22. The test strip or sheet of claim 16, wherein the strip or sheet is inserted into a housing.

23. A lateral flow device, comprising a test strip or sheet, wherein said test strip or sheet comprises:

(i) a strip or sheet comprising a dry porous material having immobilized thereon in an analyte detection zone (a) a 5-pentylresorcinol/macromolecular carrier conjugate wherein 5-pentylresorcinol is conjugated via a hydroxyl group or a derivative thereof on its benzene ring to the carrier, or (b) an antibody capable of binding both THC and said conjugate; and

(ii) joined to, or integral to, said strip or sheet providing said analyte detection zone, a label release zone containing either said antibody in labeled form, if said analyte detection zone presents immobilized 5-pentylresorcinol/carrier conjugate, or, if said analyte detection zone presents immobilized antibody, detectable 5-pentylresorcinol conjugate, whereby said labeled antibody or detectable conjugate will be released into a liquid sample drawn into the label release zone.

24. A kit comprising:

(a) a 5-pentylresorcinol/macromolecular carrier conjugate wherein 5-pentylresorcinol is conjugated via a hydroxyl group or a derivative thereof on its benzene ring to the carrier; and

(b) an antibody capable of binding both THC and said conjugate.

25. The kit as claimed in claim 24 wherein a direct label or secondary labeled antibody is provided for labeling said antibody.

26. The kit as claimed in claim 24 wherein said conjugate is a detectable conjugate.

27. The kit as claimed in claim 24, wherein said antibody or said conjugate is immobilised on a solid support.

28. The kit as claimed in claim 27, wherein the solid support is used in a lateral flow chromatography assay.